BioXcel Therapeutics rises after agitation drug meets main goal in at-home study

BioXcel Therapeutics

27/08/2025 12:42

** Shares of biopharma firm BioXcel Therapeutics BTAI.O rise 11.1% to $5.82 premarket

** Company says its experimental agitation drug met the main goal of a late-stage study testing it in patients with bipolar disorder or schizophrenia for at-home use

** The drug, BXCL501, also known as dexmedetomidine, is sold as Igalmi in the United States for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in medically supervised settings

     ** Data from this 200-patient trial could help in potentially expanding the approval for the drug for at-home use

** Company plans to submit an application for expanded approval for the drug in Q1 2026 for at-home use

** Up to last close, stock down 12.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))